Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients: * Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments. * Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.

NCT Number	NCT04681417
Lead Sponsor	Institut Curie Collaborators: Fondation Rothschild Paris
Conditions	Retinoblastoma
Enrollment	225 participants
Start Date	2021-03-25
Primary Completion	2035-01-20 (estimated)
Study Completion	2036-01-20 (estimated)
Updated on ClinicalTrials.gov	2025-11-28